Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Up To 50 SAR OFF Your First Order Use Code : APP50 | Get Free Delivery With No Minimum Order

Hotline :   920008144 Download app now
Magazine
Enjoy free Shipping 🚚 ‎ ‎ ‎ ‎ ‎ ‎Shop from over 12000 products 🔥 ‎ ‎ ‎ ‎ ‎ ‎Fast Delivery 🚀
Almujtama Pharmacy logo
OMIZ 20/MG CAP 14/CAP
OMIZ 20/MG CAP 14/CAP
45.95
OMIZ 20MG 14TAB

Frequently bought together

Brand : OMIZ

OMIZ 20/MG CAP 14/CAP

45.95
  • Sku : I-004614
  • Key features

    OMIZ 20MG 14TAB is a capsule formulation of OMIZ containing omeprazole 20 mg, a proton pump inhibitor. It irreversibly inhibits the gastric parietal cell H+/K+-ATPase (proton pump), blocking the final step of gastric acid secretion. It is indicated for acid-related disorders including gastroesophageal reflux disease (with or without erosive esophagitis), peptic ulcer disease (duodenal and gastric ulcers), Helicobacter pylori eradication as part of combination therapy, and pathological hypersecretory conditions such as Zollinger-Ellison syndrome, and may be used for NSAID-associated ulcer treatment or prevention per local labeling. Available in capsule form in packs of 14.

     

    • Brand: OMIZ
    • Active Ingredient: OMEPRAZOLE 20mg
    • Strength: 20mg
    • Dosage Form: Capsule
    • Pack Size: 14 Capsules
    • Route: Oral use
    • Prescription Status: Prescription
    • Therapeutic Class: Gastrointestinal
    • Pharmacological Group: Proton Pump Inhibitors
    • Drug Class: Proton Pump Inhibitor (PPI)
    • Manufacturer: TABUK PHARMACEUTICAL MANUFACTURING CO.
    • Country of Origin: Saudi Arabia
    • SFDA Registration No.: 1707257772
    • Shelf Life: 24 months
    • Storage: store below 25°c
    • Gi Condition: Acid Reflux/GERD, Ulcer

Frequently bought together

Description
Specification

Indications

Approved Uses

Acid-related disorders including GERD (with/without erosive esophagitis), peptic ulcer disease (duodenal and gastric ulcers), Helicobacter pylori eradication as part of combination therapy, and pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome); also used for NSAID-associated ulcer treatment/prevention depending on local labeling.

Dosage & Administration

Dosing by Condition

Typical adult dosing: GERD (symptomatic): 20 mg once daily for 4 weeks (may extend to 8 weeks if needed). Erosive esophagitis: 20 mg once daily for 4-8 weeks (some patients may require 40 mg daily per severity/label). Duodenal ulcer: 20 mg once daily for 4 weeks. Gastric ulcer: 20-40 mg once daily for 4-8 weeks. H. pylori eradication: 20 mg twice daily for 10-14 days with appropriate antibiotics (regimen-dependent). Zollinger-Ellison: start ~60 mg once daily and titrate; doses >80 mg/day should be divided.

Initial Dose

20mg once daily.

Maintenance Dose

20mg once daily

Maximum Dose

120mg per day (Zollinger-Ellison syndrome); 40mg per day for standard indications

Children's Dosage

Children 1-11 years (body weight 10-19kg): 10mg once daily; body weight ≥20kg: 20mg once daily. Children ≥12 years: 20-40mg once daily. Not recommended in children under 1 year

How to Take

Take orally on an empty stomach, ideally 30-60 minutes before a meal (often before breakfast). Swallow the capsule whole with water; do not crush or chew. If unable to swallow, the capsule may be opened and the enteric-coated granules sprinkled on a small amount of soft/acidic food (e.g., applesauce) and swallowed immediately without chewing; do not store the mixture.

Side Effects

Common Side Effects

Headache, nausea, diarrhea, abdominal pain, flatulence, constipation, vomiting, dizziness

Safety & Warnings

Contraindications

Hypersensitivity to omeprazole, substituted benzimidazoles, or any excipient; concomitant use with rilpivirine-containing products; concomitant use with nelfinavir

Warnings & Precautions

May mask gastric malignancy-evaluate alarm features; long-term use associated with hypomagnesemia, fractures, and vitamin B12 deficiency; risk of C. difficile diarrhea; acute interstitial nephritis; possible drug-induced lupus; consider interaction risk (e.g., clopidogrel/warfarin/phenytoin) and reassess ongoing need for chronic therapy.

Age Restriction

Pediatric use is condition- and formulation-specific; generally approved/used in children ≥1 year for GERD/erosive esophagitis, and in infants (≥1 month) only for limited indications under specialist direction-this 20 mg capsule is typically not suitable for infants.

Driving Warning

Safe

Drug Interactions

Drug Interactions

Key interactions: clopidogrel (reduced activation via CYP2C19 inhibition-avoid/consider alternative PPI), high-dose methotrexate (delayed clearance-consider holding PPI), warfarin (↑INR/bleeding-monitor), phenytoin/diazepam/cilostazol (↑levels via CYP2C19-monitor), digoxin (↑absorption-monitor), drugs needing acidic pH (e.g., ketoconazole/itraconazole/posaconazole, iron salts-reduced absorption), antiretrovirals with pH dependence/contraindications (rilpivirine contraindicated; atazanavir/nelfinavir reduced exposure), tacrolimus (↑levels-monitor), and strong CYP inducers (rifampin, St. John’s wort) may reduce omeprazole effect.

Interaction Severity

MAJOR/Contraindicated: rilpivirine; nelfinavir (and generally avoid with atazanavir due to reduced absorption/exposure). IMPORTANT/Clinically significant: clopidogrel (reduced activation via CYP2C19-avoid or consider alternative PPI if needed). MODERATE: warfarin (monitor INR), high-dose methotrexate (consider temporary PPI hold), tacrolimus (monitor levels), phenytoin (monitor levels), digoxin (monitor in high-risk), azole antifungals requiring acidity (reduced absorption).

Food Interaction

Take on an empty stomach, 30-60 minutes before a meal for best effect.

Special Populations

Pregnancy

Category C

Children

Children 1-11 years (body weight 10-19kg): 10mg once daily; body weight ≥20kg: 20mg once daily. Children ≥12 years: 20-40mg once daily. Not recommended in children under 1 year

Elderly

Standard adult dosing; no routine dose adjustment required, but monitor for hypomagnesemia and bone fracture risk with long-term use

Kidney Impairment

No adjustment needed.

Liver Impairment

Mild-moderate hepatic impairment: usually no adjustment; severe hepatic impairment: use the lowest effective dose and generally do not exceed 20 mg/day.

Storage & Patient Advice

Stopping the Medicine

Safe to stop after short-term courses; after prolonged use, rebound acid hypersecretion can occur-consider step-down/taper and reassess indication with a clinician.

Patient Counseling

Take on an empty stomach 30-60 minutes before a meal; swallow capsule whole (or sprinkle granules on a small amount of soft food and swallow without chewing if needed). Seek care for persistent/severe diarrhea, rash, or signs of low magnesium; discuss long-term risks (fracture risk, B12 deficiency) if prolonged therapy. Tell your clinician about all medicines, especially clopidogrel, warfarin, tacrolimus, phenytoin, and certain HIV medicines (rilpivirine/nelfinavir/atazanavir).

Monitoring Requirements

Short-term: usually no routine labs. Long-term/prolonged therapy: consider magnesium (especially if >3 months or with diuretics), assess for vitamin B12 deficiency with prolonged use, consider bone/fracture risk in high-risk patients, and monitor INR if on warfarin; monitor for renal adverse effects (e.g., AIN) if symptomatic.

Pharmacology

Mechanism of Action

Irreversibly inhibits the gastric parietal cell H+/K+-ATPase (proton pump), blocking the final step of gastric acid secretion.

Onset of Action

Onset within ~1 hour; maximal acid suppression after a single dose occurs within a few hours, but full therapeutic effect typically requires 1-4 days of daily dosing.

Duration of Effect

Approximately 24 hours of acid suppression per dose, with maximal/steady effect reached after ~3-4 days of daily dosing.

Half-Life

0.5-1.2 hours.

Bioavailability

Oral bioavailability is ~30-40% after a single dose and increases to ~60% with repeated dosing (range varies by individual and formulation).

Metabolism

Extensive hepatic metabolism primarily via CYP2C19, with contribution from CYP3A4.

Excretion

Approximately 77% renal excretion (as metabolites), 20% fecal.

Protein Binding

Approximately 95%.

Product Information

Available Dosage Forms

For this product: oral capsule 20 mg (SFDA-verified). Omeprazole as an active ingredient is also available in other markets/forms (e.g., delayed-release tablets/capsules, powder for oral suspension, and IV injection), but those are not the dosage form of OMIZ 20MG CAP.

Composition per Dose

Each capsule: 20mg omeprazole (as enteric-coated granules)

Generic Availability

Yes

OTC Alternatives

OTC options for mild/intermittent symptoms include antacids (e.g., calcium carbonate; aluminum/magnesium hydroxide) and H2-receptor antagonists (e.g., famotidine).

Gi Condition

Acid Reflux/GERD, Ulcer

 

Legal Disclaimer - Al Mujtama Pharmacy

The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Al Mujtama Pharmacy assumes no legal or medical liability for:

  • Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist
  • Any discrepancy between the information provided and the product's package insert or SFDA guidelines
  • Any misuse of medication resulting from personal interpretation of the content displayed

Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication.

By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation.

Your health is a trust - always consult your doctor first.

Similar Products

whatsapp